Burnout and compassion fatigue are putting everyone at risk
The toll of COVID-19 on healthcare workers has been brutal, with many wanting to call it quits. The WHO says burnout, coupled with an ageing…
Sophie Attwood
Sophie is a journalist at Australian Doctor.
Patients with dermal fillers are facing this possible COVID-19 complication
The growing list of COVID-19 complications is long and surprising — from brain changes and heart disease to skin rashes and COVID toes. Those who…
While some GP practices struggle, others are more profitable than law firms
Almost all GPs and most non-GP specialists run private businesses to provide medical care in Australia. Business decisions can influence the costs of medical care,…
I spend a lot of time minding my pees and queues
I’m standing in an airport queue after a medical conference, patiently waiting for the bag-tag machine, smugly grateful that I checked in on my phone,…
Body piercings may be artistic, but I’ve seen what can go wrong
Throughout history, body piercing has been a symbol of beauty, sexuality, ritual initiation and rites of passage. Mayan royalty had their tongues and genitals pierced;…
My patient swears colchicine is a panacea for her three painful conditions
My patient is no stranger to pain, but it seems that, over our past couple of visits, I have eliminated or mitigated all her painful…
It’s general practice that’s broken, and it’s general practice that needs to be fixed
The survivability crisis facing general practice that many of us in the profession have been thinking about, talking about and predicting for some time is…
Mums who recognise others’ happiness are more responsive to their babies
Eyes wide, a baby reaches for a toy. Her caregiver, sensing her interest, brings the toy within her grasp. “Ga!” the baby exclaims, and her…
Hey, Dr Nisselle, you were lucky – we were on call for 156 hours!
I must respond to Dr Paul Nisselle’s article ‘How we became doctors in the old days — in 8 steps’, a Medical Observer opinion piece,…
New Alzheimer’s drug could be available next year, but are the risks worth the reward?
Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data…
